Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis

Therapeutics and Clinical Risk Management

Volumn 3, Issue 5, 2007, Pages 919-927

  Kedia, Prashant ^a   Cohen, Russell D ^b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Balsalazide; Inflammatory bowel disease; Mesalamine; Olsalazine; Sulfasalazine; Ulcerative colitis

Indexed keywords

BALSALAZIDE; LIALDA; MESALAZINE; MEZAVANT; MICROSPHERE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; SPD 476; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BEDTIME DOSAGE; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DELAYED RELEASE FORMULATION; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPEPSIA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; MAINTENANCE DRUG DOSE; NAUSEA; PATIENT COMPLIANCE; PHARMACODYNAMICS; QUALITY OF LIFE; RECURRENCE RISK; REMISSION; REVIEW; RHINITIS; STOMACH PH; ULCERATIVE COLITIS;

EID: 36448937855     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Ahnfelt-Ronne I, Nielsen OH, Christensen A, et al. 1990. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology, 98:1162-9.
2. Ardizzone S, Doldo P, Ranzi T, et al. 1999. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group. Ital J Gastroenterol Hepatol, 31:677-84.
3. Baron JH, Connell AM, Lennard-Jones JE, et al. 1962. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet, 1: 1094-6.
4. Burress GC, Musch MW, Jurivich DA, et al. 1997. Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells. Gastroenterology, 113:1474-9.
5. Casellas F, Arenas JI, Baudet JS, et al. 2005. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis, 11:488-96.
6. Casellas F, Lopez-Vivancos J, Badia X, et al. 2001. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol, 13:567-72.
7. Cohen RD. 2006. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther, 24:465-74.
8. Cohen RD, Woseth DM, Thisted RA, et al. 2000. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol, 95:1263-76.
9. Courtney MG, Nunes DP, Bergin CF, et al. 1992. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet, 339:1279-81.
10. d'Albasio G, Pacini F, Camarri E, et al. 1997. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol, 92:1143-7.
11. D'Haens G, Hommes D, Engels L, et al. 2006. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther, 24:1087-97.
12. De Vos M, Verdievel H, Schoonjans R, et al. 1992. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral S-ASA preparations. Gut, 33:1338-42.
13. Dick AP, Grayson MJ, Carpenter RG, et al. 1964. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut, 5:437-42.
14. Eaden JA, Abrams KR, Mayberry JF. 2001. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48:526-35.
15. Fallingborg J, Christensen LA, Ingeman-Nielsen M, et al. 1989. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther, 3:605-13.
16. Fallingborg J, Christensen LA, Jacobsen BA, et al. 1993. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci, 38:1989-93.
17. Farmer RG, Easley KA, Rankin GB. 1993. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci, 38:1137-46.
18. Floren CH, Benoni C, Willen R. 1987. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol, 22:459-62.
19. Frieri G, Giacomelli R, Pimpo M, et al. 2000. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut, 47:410-4.
20. Frieri G, Pimpo MT, Palumbo GC, et al. 1999. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther, 13:1413-7.
21. Gendre JP, Mary JY, Florent C, et al. 1993. Oral mesalainine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology, 104:435-9.
22. Ghosh S, Shand A, Ferguson A. 2000. Ulcerative colitis. BMJ, 320:1119-23.
23. Giaffer MH, Holdsworth CD, Lennard-Jones JE, et al. 1992. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther, 6:479-85.
24. Gionchetti P, Ardizzone S, Benvenuti ME, et al. 1999. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther, 13:381-8.
25. Green JR, Gibson JA, Kerr GD, et al. 1998. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther, 12:1207-16.
26. Green JR, Lobo AJ, Holdsworth CD, et al. 1998. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology, 114:15-22.
27. Green JR, Swan CH, Gibson JA, et al. 2004. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3 -year prospective observational study. Aliment Pharmacol Ther, 19:435-42.
28. Hanauer S, Good LI, Goodman MW, et al. 2000. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol, 95:1749-54.
29. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol, Nov 2005; 100(11):2478-85.
30. Hanauer S, Schwartz J, Robinson M, et al. 1993. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol, 88:1188-97.
31. Hawkey CJ, Boughton-Smith NK, Whittle BJ. 1985. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig Dis Sci, 30:1161-5.
32. Hendriksen C, Kreiner S, Binder V. 1985. Long term prognosis in ulcerative colitis - based on results from a regional patient group from the county of Copenhagen. Gut, 26:158-63.
33. Kamm MA, Sandborn WJ, Gassull M, et al. 2007. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology, 132:66-75.
34. Kane S, Huo D, Aikens J, et al. 2003. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med, 114:39-43.
35. Kane S, Huo D, Magnanti K. 2003. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol, 1:170-3.
36. Kane SV, Cohen RD, Aikens JE, et al. 2001. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol, 96:2929-33.
37. Kovvali G, Das KM. 2005. Molecular mimicry may contribute to pathogenesis of ulcerative colitis. FEBS Lett, 579:221-6.
38. Kruis W, Judmaier G, Kayasseh L, et al. 1995. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol, 391-6.
39. Langholz E, Munkholm P, Davidsen M, et al. 1996. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol, 31:260-6.
40. Lichtenstein GR, Kamm MA, Boddu P, et al. 200. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol, 5:95-102.
41. Ligumsky M, Karmeli F, Sharon P, et al. 198 1. Enh ed thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology, 81:444-9.
42. Lim WC, Hanauer SB. 2004. Controversies with aminosalicylates; in inflammatory bowel disease. Rev Gastroenterol Disord, 4:104-17.
43. Loftus EV, Jr. Silverstein MD, Sandborn WJ, et al. 2000. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut, 46:336-43.
44. Mansfield JC, Holden H, Tarlow JK, et al. 1994. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin- 1 receptor antagonist. Gastroenterology, 106:637-42.
45. Miner P, Hanauer S, Robinson M, et al. 1995. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci, 40:296-304.
46. Modigliani R, Colombel JF, Dupas JL, et al. 1996. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology, 110:688-93.
47. Myers B, Evans DN, Rhodes J, et al. 1987. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut, 28:196-200.
48. Nielsen OH. 1982. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol, 17:389-93.
49. Pokrotnieks J, Marlicz K, Paradowski L, et al. 2004 Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther, 14:1191-8.
50. Prantera C, Viscido A, Biancone L, et al. 2005. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis, 11:421-27.
51. Rachmilewitz D. 1989. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ, 298:82-6.
52. Riley SA, Mani V, Goodman MJ, et al. 1988a. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology, 94:1383-9.
53. Riley SA, Mani V, Goodman MJ, et al. 1988b. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut, 29:669-74.
54. Safdi M, DeMicco M, Sninsky C, et al. 1997. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol, 92:1867-71.
55. Sandborn WJ, Hanauer SB. 2003. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmaco Ther, 17:29-42.
56. Santucci L, Wallace J, Mencarelli A, et al, 2005. Different sensitivity of lamina propria T-cell subsets to nitric oxide-induced apoptosis explains immunomodulatory activity of a nitric oxide-releasing derivative of mesalamine in rodent colitis. Gastroenterology, 128:1243-57.
57. Shale MJ, Riley SA. 2003. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 18:191-8.
58. Singleton JW, Hanauer SB, Gitnick GL, et al. 1993. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology, 104:1293-301.
59. Sninsky CA, Cort DH, Shanahan F, et al. 1991. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study Ann Intern Med, 115:350-5.
60. Sutherland L, Macdonald JK. 2006a. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (2):CD000543.
61. Sutherland L, Macdonald JK. 2006b. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Sys Rev, (2):CD000544.
62. Sutherland L, Roth D, Beck P, et al. 2000. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Sys Rev, 2.
63. Sutherland L, Roth D, Beck P, et al. 2002. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev, (4):CD000544.
64. Sutherland LR, Martin F, Bailey RJ, et al. 1997. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology, 112:1069-77.
65. The Mesalamine Study Group. 1996. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med, 124:204-11.
66. Travis SP, Tysk C, de Silva HJ, et al. 1994. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut, 35:1282-6.
67. van Hees PA, van Tongeren JH. 1982. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol, 4:333-6.
68. Wen Z, Fiocchi C. 2004. Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol, 11:195-204.
69. Wright JP, O'Keefe EA, Cuming L, et al. 1993. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci, 38:1837-42.
70. Yang H, Rotter JI, Toyoda H, et al. 1993. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest, 92:1080-4